Jaguar Health Files 8-K: Corporate Details Updated

TL;DR

Jaguar Health (JAGX) filed an 8-K updating corporate info, including address and former name.

AI Summary

On July 23, 2024, Jaguar Health, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Financial Statements and Exhibits. The filing includes information about the company's principal executive offices located at 200 Pine Street, Suite 400, San Francisco, California, 94104, and its telephone number, (415) 371-8300. The company was formerly known as Jaguar Animal Health, Inc., with a name change occurring on August 30, 2013.

Why It Matters

This filing provides essential corporate information and updates for Jaguar Health, Inc., which is important for investors and stakeholders to stay informed about the company's official details.

Risk Assessment

Risk Level: low — The filing is primarily administrative, updating corporate details and not announcing significant financial or operational changes.

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant
• July 23, 2024 (date) — Date of earliest event reported
• 200 Pine Street, Suite 400, San Francisco, California, 94104 (address) — Principal executive offices
• (415) 371-8300 (phone_number) — Registrant's telephone number
• Jaguar Animal Health, Inc. (company) — Former company name
• August 30, 2013 (date) — Date of name change

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Mar

Filing Documents

• tm2419925d1_8k.htm (8-K) — 26KB
• tm2419925d1_ex99-1.htm (EX-99.1) — 24KB
• 0001104659-24-081721.txt ( ) — 228KB
• jagx-20240723.xsd (EX-101.SCH) — 3KB
• jagx-20240723_lab.xml (EX-101.LAB) — 33KB
• jagx-20240723_pre.xml (EX-101.PRE) — 22KB
• tm2419925d1_8k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On July 23, 2024, Jaguar Health, Inc. (the "Company") issued a press release announcing the Phase 3 OnTarget trial results for its cancer supportive care drug crofelemer. A copy of the press release is furnished as Exhibit 99.1. This Current Report on Form 8-K does not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information in Item 7.01 and the press release furnished as Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, or incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, dated July 23, 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. By: /s/ Lisa A. Conte Name: Lisa A. Conte Title: President and Chief Executive Officer Date: July 23, 2024